Back to top
more

CYTEC INDS INC (CYT)

(Delayed Data from NYSE)

$75.17 USD

75.17
1,067,107

+0.02 (0.03%)

Updated Dec 8, 2015 04:01 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

1 item in cart

View Cart/Checkout

Cyteir Therapeutics, Inc. [CYT]

Reports for Purchase

Showing records 21 - 40 ( 156 total )

Company: Cyteir Therapeutics, Inc.

Industry: Medical - Drugs

Record: 21

03/14/2022

Industry Report

Pages: 11

The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party

Company: Cyteir Therapeutics, Inc.

Industry: Medical - Drugs

Record: 22

02/01/2022

Industry Report

Pages: 18

The Wedbush Monthly Check-Up

Provider: WEDBUSH SECURITIES INC.

Analyst: CHICO L

Price: 25.00

Research Provided by a Third Party

Company: Cyteir Therapeutics, Inc.

Industry: Medical - Drugs

Record: 23

01/11/2022

Daily Note

Pages: 5

CYT-0851 Update; Busy Year Ahead

Provider: WEDBUSH SECURITIES INC.

Analyst: DRISCOLL R

Price: 5.00

Research Provided by a Third Party

Company: Cyteir Therapeutics, Inc.

Industry: Medical - Drugs

Record: 24

12/15/2021

Industry Report

Pages: 37

2021 - No Gains... Lot of Pain [2022 Outlook]

Provider: WEDBUSH SECURITIES INC.

Analyst: CHICO L

Price: 35.00

Research Provided by a Third Party

Company: Cyteir Therapeutics, Inc.

Industry: Medical - Drugs

Record: 25

12/01/2021

Industry Report

Pages: 17

Monthly Check-Up: December 2021

Provider: WEDBUSH SECURITIES INC.

Analyst: CHICO L

Price: 25.00

Research Provided by a Third Party

Company: Cyteir Therapeutics, Inc.

Industry: Medical - Drugs

Record: 26

11/19/2021

Company Report

Pages: 5

Q3 Financials; CYT-0851 RP2D Picked; Study Expands

Provider: WEDBUSH SECURITIES INC.

Analyst: DRISCOLL R

Price: 5.00

Research Provided by a Third Party

Company: Cyteir Therapeutics, Inc.

Industry: Medical - Drugs

Record: 27

11/19/2021

Daily Note

Pages: 11

MORNING CALL

Provider: WEDBUSH SECURITIES INC.

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party

Company: Cyteir Therapeutics, Inc.

Industry: Medical - Drugs

Record: 28

08/13/2021

Company Report

Pages: 6

Q2 Financials; CYT-0851 Study Broadening on Track

Provider: WEDBUSH SECURITIES INC.

Analyst: DRISCOLL R

Price: 25.00

Research Provided by a Third Party

Company: Cyteir Therapeutics, Inc.

Industry: Medical - Drugs

Record: 29

07/13/2021

Company Report

Pages: 31

Initiating with OUTPERFORM and $40 PT; A Cut Above

Provider: WEDBUSH SECURITIES INC.

Analyst: DRISCOLL R

Price: 75.00

Research Provided by a Third Party

Company: Cyteir Therapeutics, Inc.

Industry: Medical - Drugs

Record: 30

07/13/2021

Daily Note

Pages: 5

MORNING CALL

Provider: WEDBUSH SECURITIES INC.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: Cyteir Therapeutics, Inc.

Industry: Chemical - Diversified

Record: 31

11/17/2015

Company Report

Pages: 2

Weekly Arb Spread

Provider: G.RESEARCH, LLC

Price: 10.00

Research Provided by a Third Party

Company: Cyteir Therapeutics, Inc.

Industry: Chemical - Diversified

Record: 32

10/29/2015

Industry Report

Pages: 76

Specialty Chemicals Leading Indicators Through September 2015

Provider: KEYBANC CAPITAL MARKETS

Analyst: SISON M

Price: 150.00

Research Provided by a Third Party

Company: Cyteir Therapeutics, Inc.

Industry: Chemical - Diversified

Record: 33

08/13/2015

Daily Note

Pages: 15

Morning Meeting Notes

Provider: KEYBANC CAPITAL MARKETS

Price: 50.00

Research Provided by a Third Party

Company: Cyteir Therapeutics, Inc.

Industry: Chemical - Diversified

Record: 34

08/13/2015

Company Report

Pages: 4

Flight Has Landed; Downgrading to Sector Weight as CYT Is Above Our Price Target Given Solvay Deal

Provider: KEYBANC CAPITAL MARKETS

Analyst: SISON M

Price: 10.00

Research Provided by a Third Party

Company: Cyteir Therapeutics, Inc.

Industry: Chemical - Diversified

Record: 35

07/29/2015

Daily Note

Pages: 3

CYT Finds the Golden Road, Sells to Solvay for $75.25/share

Provider: KEYBANC CAPITAL MARKETS

Analyst: SISON M

Price: 10.00

Research Provided by a Third Party

Company: Cyteir Therapeutics, Inc.

Industry: Chemical - Diversified

Record: 36

07/28/2015

Daily Note

Pages: 78

Specialty Chemicals Leading Indicators Through June 2015

Provider: KEYBANC CAPITAL MARKETS

Analyst: SISON M

Price: 150.00

Research Provided by a Third Party

Company: Cyteir Therapeutics, Inc.

Industry: Chemical - Diversified

Record: 37

07/19/2015

Company Report

Pages: 7

Strong Growth Potential Is Built to Last Due to a High Quality Portfolio, Attractive on Weakness

Provider: KEYBANC CAPITAL MARKETS

Analyst: SISON M

Price: 25.00

Research Provided by a Third Party

Company: Cyteir Therapeutics, Inc.

Industry: Chemical - Diversified

Record: 38

07/16/2015

Daily Note

Pages: 3

A Little Turbulence, 2Q15 Misses, 2015 EPS Guidance Sustained

Provider: KEYBANC CAPITAL MARKETS

Analyst: SISON M

Price: 10.00

Research Provided by a Third Party

Company: Cyteir Therapeutics, Inc.

Industry: Chemical - Diversified

Record: 39

07/01/2015

Daily Note

Pages: 78

Specialty Chemicals Leading Indicators Through May 2015

Provider: KEYBANC CAPITAL MARKETS

Analyst: SISON M

Price: 150.00

Research Provided by a Third Party

Company: Cyteir Therapeutics, Inc.

Industry: Chemical - Diversified

Record: 40

05/27/2015

Industry Report

Pages: 78

Specialty Chemicals Leading Indicators Through April 2015

Provider: KEYBANC CAPITAL MARKETS

Analyst: SISON M

Price: 150.00

Research Provided by a Third Party